Chronic cough is a common complain of patients in respiratory clinic and its global
prevalence was up to 9.6%. Persistent cough of unexplained origin is a significant health
issue that occurs in up to 5% to 10% of patients seeking medical assistance for a chronic
cough and from 0% to 46% of patients referred to specialty cough clinics. Previous studies
showed that sputum prostaglandin D2( PGD2) and prostaglandin E2 (PGE2) concentrations were
significantly higher in chronic cough. And some research showed that Inhaled PGE2 /PGF2α
/PGD2 / PGI2/ 6-oxo-PGF1a could induced cough. And PGE2 /PGF2α/PGI2/thromboxane A2 (TXA2)
also increased the sensitivity of the cough reflex. All these five primary prostaglandins
were synthesized though the metabolism of arachidonic acid via the cyclooxygenase pathway.
Indomethacin is a strong inhibitor of cyclooxygenase , which decrease the level of
prostaglandins in airway. The investigator's preliminary study showed that indomethacin could
relieve cough and improve cough sensitivity of some patients with refractory cough. Therefore
this randomized, double-blind, placebo-controlled trial were designed to investigate whether
indomethacin can relive cough in patients with refractory cough and to explore the possible
mechanism of indomethacin in improving cough in patients with refractory cough.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University